Home

ChromaDex Corporation - Common Stock (CDXC)

8.5500
0.00 (0.00%)

Chromadex Corp is a biotechnology company dedicated to developing and commercializing innovative dietary supplement products and ingredients that support health and wellness

It specializes in the research and development of natural products, particularly those derived from the compound known as nicotinamide riboside, which is believed to promote cellular health and longevity. Through its proprietary technologies and scientific expertise, Chromadex aims to provide consumers with solutions that enhance overall well-being and support healthy aging, while also collaborating with various partners to expand its product offerings and market reach.

SummaryNewsPress ReleasesChartHistoricalFAQ
Here are the top movers in Wednesday's session.chartmill.com
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · March 5, 2025
Which stocks are experiencing notable movement on Wednesday?chartmill.com
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Via Chartmill · March 5, 2025
Wednesday's session: gap up and gap down stockschartmill.com
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · March 5, 2025
Insights into ChromaDex's Upcoming Earningsbenzinga.com
Via Benzinga · October 30, 2024
CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024investorplace.com
CDXC stock results show that ChromaDex missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 7, 2024
CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023investorplace.com
CDXC stock results show that ChromaDex beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 6, 2024
Earnings Preview For ChromaDexbenzinga.com
Via Benzinga · March 5, 2024
Earnings Scheduled For March 4, 2025benzinga.com
Via Benzinga · March 4, 2025
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 25, 2024
ChromaDex: Q3 Earnings Insightsbenzinga.com
Via Benzinga · November 8, 2023
Earnings Outlook For ChromaDexbenzinga.com
Via Benzinga · November 7, 2023
Recap: ChromaDex Q1 Earningsbenzinga.com
Via Benzinga · May 10, 2023
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 25, 2024
What You Missed On Wall Street This Past Fridaycontent/com
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via Talk Markets · November 3, 2024
Crude Oil Moves Higher; Apple Shares Slide After Q4 Resultsbenzinga.com
Via Benzinga · November 1, 2024
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · November 1, 2024
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Resultsbenzinga.com
Via Benzinga · November 1, 2024
Dow Jumps 400 Points; US Adds 12,000 Jobs In Octoberbenzinga.com
Via Benzinga · November 1, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 1, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · October 31, 2024
CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024investorplace.com
CDXC stock results show that ChromaDex beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Via Benzinga · June 7, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · May 8, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · March 18, 2024
Earnings Scheduled For March 6, 2024benzinga.com
Companies Reporting Before The Bell • CTS (NYSECTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
Via Benzinga · March 6, 2024